ABSTRACT OBJECTIVES This study aimed to describe the safety and short-term efficacy of the Covered Cheatham-Platinum stent (CCPS) in treating or preventing aortic wall injury (AWI) in patients with coarctation of the aorta (CoA).
C oarctation of the aorta (CoA) occurs in approximately 4 of 10,000 live births and comprises 5% to 8% of congenital heart disease (1) . When present without additional defects, CoA may not be detected until late childhood or adulthood (2) . Infants and young children with native CoA are typically treated surgically, but remain at risk for recurrent obstruction (3) . Older children and adults may be managed either surgically or percutaneously. Although surgical repair in this age group may be definitive, up to 10% of older children or adults require further intervention (4, 5) .
Balloon angioplasty of native CoA, carries a relatively higher risk of aortic wall injury (AWI) and recurrent obstruction (6) (7) (8) . This has led to the "off-label" use of bare-metal stents in older patients (9) (10) (11) (12) (13) (14) .
Although such interventions are generally safe, aortic dissection, aneurysm, and rupture have been reported, particularly in the context of severe or complex lesions (15) (16) (17) . To prevent AWI during the primary stent implantation procedure, covered stents, currently unavailable for use within the United States, have been used in Europe and elsewhere with reports of safety and efficacy (11, (18) (19) (20) (21) (22) (23) . study, patients were prospectively followed using COAST protocol. Once the COAST II study opened, these patients were included and identified as "leg- 
Inclusion criteria
Native or recurrent aortic coarctation* associated with 1 or more of the following:
Acute or chronic aortic wall injury † Nearly atretic descending aorta to 3 mm or less in diameter Genetic syndromes associated with aortic wall weakening (e.g., Marfan syndrome, Turner syndrome, familial bicuspid aortic valve with ascending aortic aneurysm) Advanced age (60 yrs or older)
Exclusion criteria
Patient size too small for safe delivery of the device (absolute exclusion of patients <20 kg), possible exclusion of patients 20 to 30 kg after discussion of risk with parents/guardians Planned deployment diameter of stent <10 mm or >22 mm Location of coarctation would require placement across a carotid artery ‡ Adults lacking capacity to consent Pregnancy *The significance of aortic obstruction was left to the judgment of the participating investigator. Indications might include mild resting aortic obstruction associated with: exercise related upper extremity hypertension; severe coarctation with multiple and/or large arterial collaterals; single-ventricle physiology; left ventricular dysfunction; ascending aortic aneurysm. †Aortic wall injury might include descending aortic aneurysm; descending aortic pseudoaneurysm; contained aortic wall rupture; noncontained rupture of the aortic wall. ‡Crossing or covering of a subclavian artery was permissible in certain situations, but only after alternative treatments had been considered. (COAST II) following protocols identical to the COAST II study.
Before enrollment, all patients and/or guardians signed informed consent for CCPS implantation and to participate in study follow-up. All patients were followed prospectively. Taggart et al.
Covered Stents for Treating/Preventing Aortic Wall Injury (COAST II) before the procedure. Catheterization was performed according to accepted standards. There was no trialspecified implantation protocol. Analgesia and/or anesthesia were administered at the discretion of the catheterizing physician. Pressure measurements were obtained proximal and distal to the CoA.
Contrast angiography was performed for measurements of the aortic arch, CoA, and descending aorta at the level of the diaphragm. The diameter of any aortic aneurysm or pseudoaneurysm was measured.
Pre-existing AWI was defined as in Table 2 . Table 2 . Endoleak was defined as residual flow of blood into the AWI after stent placement. 
Pre-existing aortic wall injury
No AWI or trivial aortic wall irregularity defined as outpouching or bulging of the aortic wall with a diameter that is <1/4 the aortic diameter at the level of the diaphragm. Small aneurysmal, pseudoaneurysmal, or contained wall rupture with bulging or outpouching of the aortic wall to a diameter that is 1/4 to 1/3 the aortic diameter at the level of the diaphragm. Moderate aneurysmal, pseudoaneurysmal, or contained wall rupture with bulging or outpouching of the aortic wall to a diameter that is >1/3 to 1/2 the aortic diameter at the level of the diaphragm. Large aneurysmal, pseudoaneurysmal, or contained wall rupture with bulging or outpouching of the aortic wall to a diameter that is >1/2 the aortic diameter at the level of the diaphragm or any noncontained rupture. This classification includes acute or rapidly expanding moderate or large aneurismal, pseudoaneurysmal, or contained outpouching >1/3 the aortic diameter or any acute, uncontained rupture.
Stent placement
Well-positioned: The stent(s) is/are located within the region of coarctation or target aortic wall injury such that the stent does not unnecessarily cross a brachiocephalic artery and does not distort the contour of the aorta. Minor malposition: The stent(s) is/are well-centered in the region of the coarctation or target aortic wall injury, but would not be considered well positioned by unnecessarily crossing and partially obstructing flow into a brachiocephalic artery and/or by causing mild distortion of the aortic contour. Major malposition: The stent(s) is/are outside of the region of coarctation or target aortic wall injury, unnecessarily crosses and totally occludes a brachiocephalic artery, or causes major distortion of the aortic contour Coverage of aortic wall injury Not Applicable. No aortic wall injury defined at baseline or after Covered Stent implantation Complete coverage of target aortic wall injury, (aneurysm, pseudoaneurysm, wall rupture) Minor endoleak* (contained residual leakage into the target wall defect with the expectation of spontaneous closure) Moderate residual contained endoleak, likely to require additional therapy Large residual endoleak or persistent uncontained, extraluminal leak requiring additional surgical therapy Appearance of aorta Smooth angiographic appearance to the vessel Therapeutic tear: Tear in the intima/media that is confined to the aortic wall in radial dimension and to the target region or irregular appearance of the vessel without dissection or aneurysm Dissection: Tear in the intima/media that extends proximally or distally from the narrowed aortic segment. Subcategory A: Dissection without obstruction to distal flow Subcategory B: Dissection with obstruction to distal flow New aneurysm or contained rupture: New bulging or outpouching of the aortic wall to a diameter that is >1/4 the aortic diameter at the level of the diaphragm *"Endoleak" refers to residual leak of blood into the pre-existing wall injury.
AWI ¼ aortic wall injury.
Taggart et al. or iliac arterial injury); or not attributable to stent, implantation, or catheterization (e.g., due to a preexisting or independent condition). The seriousness of the AE was described as being "not serious,"
"somewhat serious," or "serious," based upon previously described standards (26) . Taggart et al.
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Of the 83 patients in the Treatment group, 71 were treated with a single CCPS. Among these patients, *Changes in blood pressures and gradients remained statistically significant when analyses were repeated using generalized estimating equations models to account for the correlation of patients within sites.
SBP ¼ systolic blood pressure. *Changes in gradients and minimum diameters remained statistically significant when analyses were repeated using generalized estimating equations models to account for the correlation of patients within sites.
AAo ¼ ascending aorta; DAo ¼ descending aorta.
Taggart et al. of serious morbidity (16, 17) . The rate of acute AWI due to bare-metal stent placement has been reported between 1.0% and 4.1%; this is significantly lower than similar complications seen with balloon angioplasty alone (7, 13, 24) . In addition, late AWI is a recognized complication of bare-metal stent placement (14, 25, 31) .
Covered stents represent an appealing option for primary CoA therapy or for treating or preventing AWI. Several studies have reported success using covered stents to manage CoA as a primary therapy for native or recurrent CoA (11, (18) (19) (20) (21) (22) (23) . Others have reported the utility of covered stents for managing acute AWI with or without CoA (15, 16, 32) . Cumulatively, these reports describe a safety profile of covered stents that is similar to bare-metal stents Collapse of the Advanta V12 covered stent has been reported, presumably due to a residual endoleak, suggesting the need to recognize and treat significant endoleaks (33) .
Overall, the most significant acute complications were arterial access injuries, seen in 4 patients (3%).
These complications, though uncommon, are serious.
The rate of access vascular injury reported in this study is higher than that encountered during the initial COAST trial (24) . This difference may reflect our "high-risk" study population. Although the COAST II study specifically targeted older patients and those with genetic arteriopathy syndromes, such patients were excluded from the COAST study. In addition, the larger sheath required for delivery of the CCPS may have contributed an increased risk of arterial injury; the typical sheath size for delivery of a ture and endocarditis, and the ability to re-dilate the CCPS. We also acknowledge that our effort to describe arterial access-site injury was a retrospective review of available noninvasive, nonimaging data, and, thus, may not represent the true incidence of arterial injury.
CONCLUSIONS
The CCPS can be used to effectively treat existing AWI and may prevent AWI in patients undergoing stent therapy for CoA. Placement of the CCPS has a high rate of technical success and short-term hemodynamic improvement. We believe that these shortterm results support the use of covered stents as a safe and effective treatment option for CoA and AWI.
We anticipate that mid-to long-term follow-up of these patients will confirm this conclusion. Although overall, serious complications are uncommon, arterial access injury is a potential complication that should be investigated and treated aggressively. Covered Stents for Treating/Preventing Aortic Wall Injury (COAST II)
